ESR 15: Carina Matias
Development of a novel anibiotic treatment
Carina is involved in the investigation of microbiological properties of novel drug ATx201 including (a) assessment of potency across clinically relevant pathogens, (b) investigation into mode of action, (c) characterization of potency in different synthetic genetic backgrounds, (d) assessment of resistance evolution properties relative to currently marketed products, (e) high throughput screens for identification of novel antibiotic treatments targeting human pathogens.
UNION Therapeutics, Denmark
Danish Technical University, Novo Nordisk Foundation Center for Biosustainability, Denmark
Prof. Morten Sommer (DTU)
Prof. Ian Henderson (UNIBIR-IMI)
Prof. Jean-Pierre Simorre (CNRS)
Carina has acquired an interest for microbiology and antimicrobial resistance during her first degree in Health Sciences at the Insitute of Health Sciences Egas Moniz in Portugal (2009-2013). She subsequently finished her Master degree in Microbiology from the Technical University of Lisbon (2013-2015) with her master thesis “Quorum-sensing system of Staphylococcus aureus isolates from diabetic foot ulcers”.